Dive into why the Syngene share price fall 10% today, unpack Q4 results, expert takeaways, and see if Syngene stock is a buy, sell, or hold for FY26
What Caused the Syngene Share Price Fall 10%?
The Syngene share price fall 10% on April 24, 2025, rattled investors when the stock opened at ₹691.00—down from a ₹749.15 close the previous session—before dipping as low as ₹675.60 by mid-morning. Experts point to Syngene’s cautious FY26 outlook and an expected slowdown in new commercial deals as the core drivers behind this sharp downturn
Read more-Tech Mahindra Share Price Rallies 2% Pre-Q4 Results: What Analysts Are Saying
Q4 Financials: The Upside and the Pressure
Despite the Syngene share price fall 10%, Q4 FY25 delivered some silver linings:
- Revenue: Dropped 8% year-on-year to ₹917 cr, hurt by weak US biotech R&D spend.
- Net Profit: Climbed 6% to ₹189 cr, showing resilient bottom-line performance.
- EBITDA Margin: Improved to 36% from 33%, though EBITDA itself slipped 1% to ₹333 cr [Syngene International Investor Relations].
Short-Term and Long-Term Impacts
- Short-Term Volatility: The Syngene share price fall 10% triggers margin pressure, prompting traders to re-evaluate exposure ahead of FY26 guidance.
- Long-Term Outlook: With the Baltimore Bayview biologics plant set to start H2 2025, Syngene’s capacity buildup could fuel future growth, potentially offsetting near-term headwinds.
Sectors and Spillover Effects
The Syngene share price fall 10% isn’t isolated—it partly reflects broader biotech contracting weakness in the US. A pullback in R&D spend can ripple across:
More Read
- Contract Research Organizations (CROs): Facing delayed or downsized deals.
- Biologics Manufacturing: Slower capacity ramp-ups might cool down adjacent suppliers.
- Pharma Partnerships: Caution among big pharma on outsourcing could moderate deal pipelines.
Pros and Cons for Investors
| Pros | Cons |
|---|---|
| Improved EBITDA margin despite revenue drop. | Cautious FY26 guidance points to fewer commercial deals. |
| Strategic Baltimore acquisition could boost US footprint. | Short-term profit margins may stay under pressure. |
| Average price target of ₹1,030 implies ~52% upside [Trendlyne]. | Leadership change adds near-term execution risk. |
Syngene Share Price Target & Recommendations
Analysts peg the Syngene share price fall 10% as an entry opportunity, with a consensus target of ₹1,030—roughly a 51.9% bump from today’s ₹677.90 close. On Trendlyne, most experts advise buy, while Moneycontrol shows 40% buy, 10% sell, and 10% hold signals. Always weigh these against your investment horizon and risk appetite.
New Source- Indiahood
